Proof of efficacy pilot study with HIV/AIDS patients using AquaLiv's NatuRx™ HIV/AIDS treatment. Status: Complete
Age: 58
Gender: Female
Nationality: Japanese
Duration: Feb 2007 – Feb 2011
Observed by: Dr. Takemi Ichimura, Chief Science Officer - AquaLiv, Inc.
Patient A was diagnosed with HIV & AIDS when she was 58 years old in August 1997. Clinical test data prior to start of NatuRx™ HIV was provided to the patient by Tokyo Metropolitan Hospital. Patient A was taking antiretroviral (ARV) drugs before and during the study.
Early in her diagnosis, Patient A could no longer bear the pain caused by the antiretroviral drugs (ARVs) and openly stated she would preferred to die. Patient A volunteered for the NatuRx™ HIV Pilot Study with the hope that others may benefit from the knowledge gained during the study. Remarkably, she is presently living an ordinary life as her quality of life has been profoundly enhanced. Patient A responded to the treatment extremely well showing great increases in CD4 (good) and decreases in Viral Load (good). Patient A also gained much needed weight during the treatment.




Age: 57
Gender: Male
Nationality: Japanese
Duration: April 2008 – April 2011
Observed by: Dr. Takemi Ichimura, Chief Science Officer - AquaLiv, Inc.
Patient B volunteered for the NatuRx™ HIV Pilot Study and began treatment February 2008. He is infected with HIV as well as the Hepatitis C Virus (HCV) which was additionally monitored during the treatment. He responded to the treatment extremely well showing great increases in CD4 (good) and decreases in Viral Load (good). Remarkably, his HCV Counts plummeted during the treatment (good). (HCV Count = Hepatitis C Viral Load)






| Next > |
|---|
Last 5 tweets from aqualiv:

view all news sources
CEO's Blog
Statements made on this website have not been evaluated by the Food and Drug Administration. The products represented on this website are not intended to diagnose, treat, cure or prevent any disease. For medical advice, please consult with your physician.